# A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

> **NCT00144105** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 562 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TPV500mg/RTV200mgBID
- **DRUG:** TPV500mg/RTV100mgBID
- **DRUG:** LPV400mg/RTV100mgBID

## Key facts

- **NCT ID:** NCT00144105
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 562 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144105, "A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00144105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*